Article

Microcoaxial phaco better than standard phaco

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification.

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification, according to Seyed Javad Hashemian and colleagues from the Fajr Hospital & Negah Eye Hospital, Tehran, Iran.

In a controlled prospective clinical trial, 69 eyes of subjects with senile cataract (grade 3 to 4 on the Lens opacities Classification System III) underwent phacoemulsification. The subjects were randomized to undergo either microcoaxial phaco (39 eyes; Sovereign WhiteStar; AMO) or conventional phaco (30 eyes; Legacy 20000, Everest; Alcon). In each case, the incision was made into a temporarily clear cornea and a hydrophobic acrylic flexible intraocular lens (Acrysof Natural, SN60AT; Alcon) was implanted.

The researchers found that the only statistically significant difference between the two groups was the surgically induced keratometric changes at five days postoperatively. (p=0.02).

At the study's conclusion, Dr Hashemian an colleagues concluded that, although both techniques were safe and effective for cataract surgery, microcoaxial phacoemulsification induced significantly less surgical keratometric changes and yielded better visual acuity in the early postoperative days.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.